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Stem cell transplantation and novel chemotherapeutics such as thalidomide, lenalidomide and bortezomib have revolutionized the management of MM, extending the overall survival and the 5-year relative survival rates from 25% (in 1977) to 41% (in 2007). Nonetheless, patients systematically relapse despite the achievement of complete remission. 5 Therefore, despite decades of research, MM remains an incurable disease.
In recent years, the molecular bases of such fatal outcome have been partially discovered and novel potential pharmacological targets have been identified. Among these, Notch receptors and their ligands have gained growing interest as they affect multiple features of the disease, including tumor cell growth, resistance to apoptotic stimuli and chemotherapeutics, angiogenesis, 6 immune system modulation and ability to trigger bone lesions. [6] [7] [8] [9] [10] Here we will review the known roles played by Notch pathway in MM and we will present a model describing possible additional Notchdriven pathogenetic mechanisms.
THE 'BONE NICHE' PROMOTES MM MALIGNANCY
MM cells can be considered per se nontumoral long-lived plasma cells as they strictly depend on the BM microenvironment for survival and disease progression. 11 Such microenvironment consists of a 'niche' containing extracellular matrix (ECM) and BM stromal cells (BMSCs), including fibroblasts, osteoclasts (OCs), osteoblasts, vascular endothelial cells and lymphocytes. The crosstalk between MM and the BM niche triggers dramatic alterations in the BM microenvironment, of which the most evident effect is osteolytic bone destruction. 12 Such cross-talk is mediated by soluble factors (cytokines) and by adhesion molecules. 13 In addition to osteolysis, the reciprocal signaling between MM cells and BMSCs results in other critical biological phenomena: (1) homing of malignant cells to the BM, (2) spread of the tumor through the blood to multiple bone sites, (3) production of tumor survival factors, (4) inhibition of osteoblastogenesis, (5) angiogenesis and (6) immune suppression.
The BM niche plays a critical role from a clinical perspective, as the presence and extent of bone involvement positively correlate with tumor burden and disease stage, and are indicative of poor prognosis.
14 Notch receptors and their ligands are single-pass transmembrane proteins able to modulate the interplay between MM cells and the BM niche at multiple levels. [6] [7] [8] [9] [10] [15] [16] [17] [18] In the next section, we will discuss the bases of Notch pathway activation and the main outcomes in MM cells.
NOTCH PATHWAY ACTIVATION AND ITS ALTERATIONS IN THE BIOLOGY OF MM CELLS
Notch is a family of transmembrane proteins acting as receptors and transcription factors at the same time. In mammals, four Notch isoforms (Notch1-4) are known, together with two classes of Notch ligands, namely Jagged1-2, and Dll-1/3/4. Notch structure and its activation mediated by ligand on adjacent cells is illustrated in Figure 1 . Notch signals finely tune the balance between self-renewal and differentiation in a number of normal tissues, as well as in cancerous cells. We have recently reviewed evidences and controversies about the Notch pathway role in B-cell lineage malignancies. 8 Accumulating evidences show that the Notch pathway plays relevant roles in MM. Notch activation not only has dramatic outcomes directly in tumor cells, but also in the surrounding microenvironment, thus playing a critical role in delivering the signals deriving from tumor cells to the microenvironment and vice versa ( Table 1) .
Notch activation in malignant plasma cells may occur in two distinct ways: MM cells simultaneously express Notch1-3 and their ligands Jagged1-2, 7, 18 resulting in an autonomous pathway activation through homotypic interactions, or Notch activation can be triggered by BMSCs expressing Dll 10 or Jagged 7 ligands.
The following works recapitulate the dual mechanism of Notch signaling activation in MM cells by homotypical (reciprocal activation by MM cells) or heterotypical (BMSCs-mediated activation) cell interaction. Jundt et al. 7 found that Notch-1 and Notch-2 receptors and their ligand Jagged1 were highly expressed in cultured and primary MM cells. In addition, Notch receptors were deregulated in CD19 low CD38 high malignant plasma cells, but not in CD19 þ normal B cells from the same subjects, indicating that Notch pathway alterations were specific of the malignant clones. Jagged1 was also detected in BMSCs from MM patients, and HtTA-jag10 fibroblasts expressing human Jagged1 induced Notch hyperstimulation in MM cell lines, resulting in increased expression of the Notch target HES1 and accelerated MM cell proliferation, which was blocked by the addition of DAPT, a wellcharacterized g-secretase inhibitor (GSI) widely used to block the generation of active intracellular Notch. Houde et al. 6 reported that only malignant cells, but not nonmalignant plasma cells from healthy individuals or patients with other malignancies, overexpressed Jagged2. Interestingly, aberrant Jagged2 expression characterizes a premalignant condition, as it was found in all of the subjects with MGUS. 6 A further breakthrough result of this study is that Jagged2 is responsible for the ability of MM cells to induce Notch activation in MRC5 fibroblasts (a surrogate of BMSCs) and also increases the production of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) by stromal cells. As IL-6, VEGF and IGF-1 are critical inducers of malignant plasma cell survival and are correlated with poor prognosis, 19 this finding indicates that Jagged2-mediated Notch aberrant activation significantly participates in the vicious cycle established by MM cells in the BM niche. The observed Jagged2 deregulation is because of promoter hypomethylation 6 or aberrant expression of Skeletrophin in MM cells. 18 Skeletrophin is a ubiquitin ligase binding the intracellular region of the Notch ligand Jagged2 and is found to be required for Jagged2-driven Notch activation in stromal cells by MM cells. 18 An alternative mechanism of Jagged2 upregulation is the loss of SMRT/NCoR2 corepressor, which results in abnormal acetylation of the Jagged2 promoter region. 15 In conclusion, it appears that tumor cells express the Notch ligands Jagged1 and Jagged2 by the activation of two different mechanisms in different phases of MM progression; Jagged2 deregulation occurs earlier at the MGUS stage, whereas that of Jagged1 occurs only with the transition to malignant MM.
The above evidences indicate that Notch signaling deregulation occurs in plasma cells early or later during MM pathogenesis and significantly contribute to the interaction of MM cell with the BM microenvironment. Consistently, studies relying on Notch inhibition approaches univocally indicate that in MM cells Notch pathway promotes resistance to apoptotic stimuli 17 and protection from chemotherapy-induced toxicity, 16 differently from other B-cell malignancies, such as B-cell acute lymphoblastic leukemia, where Notch activation may act as a tumor suppressor. 20, 21 Recent evidences further support a model in which Notch activation promotes MM growth and accelerates the disease course by promoting cancer stem cell self-renewal. 10, 22 Although it is still a matter of debate whether the origin of MM stem cells are plasma cells or B cells, 10, 22 490% of these two populations express Notch1, indicating a possibility for Notch signaling to be activated. Chiron et al. 22 confirmed this role by showing that blocking Notch activation by antibody to Notch1 and Notch2 impairs colony formation. In addition, they reported that MM cell lines displaying clonogenic activity express the higher levels of Jagged2 whose silencing through RNA interference blocked spontaneous clonogenic growth in vitro and tumor formation in severe combined immunodeficient mice. 10, 22 Xu et al. 10 reported that Notch signaling activation can be induced by Dll1 found in BMSCs from both normal donors and ) and one intracellular, the latter containing a transmembrane domain (TD) and an intracellular domain (ICD). Notch precursor (pre-Notch) is produced in the endoplasmic reticulum as a single amino acid chain (1), then it is fucosylated and transferred to the Golgi apparatus (2) , where a furin protease splits the ECD from the TD-ICD (3). Then, the heterodimer is assembled through noncovalent bounds and reaches the cell membrane upon glycosylation. The ECD blocks Notch activation, unless it binds the ligands (Jagged or DLLs) expressed by an adjacent cell (4) . Such interaction disrupts the hetero-dimer conformation (5), allowing the ADAM (a disintegrin and metalloproteinase domain) proteinase to cut the TD-ICD extracellularly (6) . Immediately after that, the g-secretase complex cuts the TD-ICD (7) releasing the ICD, which translocates to the cell nucleus (8) . This third proteolytic processing is inhibited by GSI. Here, the ICD interacts with the CSL DNA-binding proteins (from CBF1/RBP-J in vertebrates, Suppressor of hairless in Drosophila, Lag1 in Caenorhabditis elegans), converting CSL from a transcriptional repressor to an activator (9) by displacing corepressors (Co-R) and recruiting histone acetyltransferases and co-activators, such as mastermindlike proteins (MAML). Notch targets genes, such as HES-1 and C-MYC, are then activated (10) . 23 There are several intriguing evidences pointing to a possible role for Notch signaling in mediating these critical events. In the following paragraphs, we will discuss the evidences supporting the model in which Notch signals contribute to regulate such complex interactions altering the natural history of the disease and orchestrating the development of the 'MM bone niche'.
Metastasis is the major factor affecting survival in most patients with cancer, and MM makes no exception. However, multiple bone lesions characteristic of MM are different from metastatic sites originated by solid tumors, as unlike other malignancies, in MM there is no evidence for the existence of a primary tumor site different from secondary lesions. 24, 25 It is now clear that MM originates from a transformed post-germinal-center B cell. 23 Therefore, to establish bone disease, these transformed cells have to selectively migrate to the BM. Although BM MM cells are the most abundant neoplastic cell type, few MM cells are present in the peripheral blood. These circulating cells may represent the tumor-spreading component of the disease. The hypothesis that MM cells are able to recirculate, to extravasate and to migrate to the BM is supported by recent findings. 26 In summary, MM cells are constantly invading new BM sites in a mechanism of systemic re-circulation.
The process of MM cell migration and homing closely resembles that of normal leukocytes. The deregulated expression of chemokine receptors plays a critical role in determining the ability of MM cells to reach multiple sites. 27 Once MM cells interact with and adhere to the microvessel lumen in the BM vasculature, chemokine gradients trigger the active movement of malignant cells through the vasculature toward the BM stroma. Accordingly, MM cell expression of functional chemokine receptors (CKR) inducing migration in vitro, such as CXCR4, 28 31 and CCR3, 31 allows their recruitment within the BM along a gradient of chemokines secreted by BMSCs and BM-residing MM cells. 32 Stromal cells isolated from BM samples of MM patients produce the CCR2 ligands monocyte chemoattractant proteins (MCPs) 1, 2 and 3, the CCR1 and CCR5 ligand macrophage inflammatory protein-1a (MIP-1a), 33 the CCR6 ligand MIP-3a, 34 and the CXCR4 ligand stromal cell-derived factor-1 (SDF1). 35 BM-residing MM cells are a further source of chemokines relevant for MM cell recruitment. Indeed, MIP-1a is expressed by malignant plasma cells from patients and in the 5TGM1 model of the disease.
36 CD138
þ malignant plasma cells also express significant levels of SDF1.
37
A possible role of Notch signaling in MM cell BM homing stems from the evidence from our laboratory and others that Notch controls the expression and functions of specific CKR, including CCR6, 38 CCR7, CCR5, CCR9, 39,40 CCR4, CCR8, CXCR6, 41 and CXCR4. [42] [43] [44] The CXCR4/SDF1 system promotes MM cell localization at the BM and osteolytic lesions [45] [46] [47] and is associated with poor prognosis and disease progression. 48 CXCR4 signaling favors malignant plasma cell recruitment from the periphery to the BM by affecting MM cell migration in response to SDF1, 45 which is primarily expressed by BMSCs, [49] [50] [51] [52] and may be further increased by MM cell secretion. 53 We will focus on the role of CXCR4/SDF1 axis, as it represents the main driving force inducing the migration of MM cells to the BM 54 and our recent results support a role of Notch in CXCR4-mediated migration of MM cells to the BM. 44 Abbreviations: IGF-1, insulin-like growth factor-1; IL-10, interleukin-10; MM, multiple myeloma; MMP-9, matrix metalloprotease 9; NF-kB, nuclear factor-kB; OB, osteoblast; OC, osteoclast; PDGF-B, platelet-derived growth factor subunit B; TGF-b, transforming growth factor-b; Th1, T helper type 1 cells; T-reg, T regulatory cells; VEGF, vascular endothelial growth factor. The Notch pathway leads the interactions between neoplastic cells and microenvironment and is involved in several tumor-associated processes.
a Mechanisms reported in other contexts.
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Indeed, Notch signaling promotes the expression of CXCR4 and SDF1 in MM cells. 44 Notch pathway inhibition, obtained by the gamma-Secretase inhibitor GSI-XII (Calbiochem EMD Biosciences, Inc., La Jolla, CA, USA) or through the hydrocarbon-stapled peptide SAHM1, hampers CXCR4 expression and SDF1 secretion by human MM cell lines. Concerning SDF1, these results suggest that residing MM cells in the BM may contribute to potentiate circulating MM cell recruitment by Notch-dependent SDF1 secretion. 44, 55 On the CXCR4 side, Notch signaling withdrawal was associated with reduced CXCR4 functions, namely chemotaxis and cell growth, and with a strong inhibition of BM localization of intravenously injected MM cells. 44 This results suggest that, in MM cells, CXCR4 signaling is promoted by Notch deregulation, and it may favor malignant plasma cell recruitment from the periphery to the BM by affecting MM cell migration in response to SDF1 as 45 secreted by BMSCs [49] [50] [51] [52] and further increased by MM cells. 53 The completion of the metastatic process requires MM cells to cross the endothelial and the subendothelial basement membrane as well. At first, MM cells in the bloodstream adhere to the BM endothelium mainly through the a4b1 integrin (VLA-4 (Very Late Antigen-4)) and CD44 that interact with and bind to VCAM-1 (vascular cell adhesion molecule 1) and hyaluronic acid, respectively. 24, 25, 32 Several evidences suggest that activated Notch in circulating MM cells might play a relevant role in the first steps of the bone homing process (Figure 2 ). Indeed, Hodkinson et al. 56 have shown that Notch1 triggers b1 integrin engagement by increasing its binding affinity through the activation of R-Ras and the simultaneous inhibition of H-Ras. In addition, CXCR4 plays a key role in the first step, promoting MM cell adhesion to VCAM-1 expressed by BM sinusoid endothelial cells 57 and the following transendothelial migration through a4b1 integrin activation. 58 Finally, Notch can contribute to the second step of matrix invasion through matrix metalloprotease 9 (MMP-9), a key invasive factor constitutively produced by MM cells, 59, 60 and under Notch control in cancer metastatization. 61, 62 NOTCH ROLE IN MM-TRIGGERED BM ANGIOGENESIS BM endothelial cells (BM-ECs) directly stimulate MM progression through the production of soluble factors or cell-cell contact. BMECs secrete VEGF, basic fibroblastic growth factor, MMP-2, MMP-9 and MCP-1. 63 In turn, BM-EC stimulation with VEGF results in the secretion of other factors relevant for MM cells, such as stem cell factor, granulocyte-macrophage colony-stimulating factor and IL-6. 64 The Notch pathway is necessary for vascular development; accordingly, deletions of both Notch receptors and ligands are invariably lethal during mouse embryo development. Notch1 mutant and Notch1/Notch4 double-mutant embryos carry severe defects in angiogenic vascular remodeling. 65 In adult vascular homeostasis, Notch3 gene mutations cause the degenerative vascular disease named CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). 66 Notch signaling contribution in orchestrating the complex angiogenesis mechanism has been extensively reviewed by Phng and Gerhardt. 67 Here, we will examine how Notch signaling may activate BM angiogenesis during MM progression (illustrated in Figure 3 ). Malignant plasma cells are mainly responsible for MM angiogenesis, as shown by the correlation between microvessel density and plasma cell infiltration. 68 First, MM cells activate Notch signaling on BMSCs, inducing the secretion of molecules that support angiogenesis. Indeed, cell lines and malignant plasma cells from MM patients overexpressing Jagged2 trigger the secretion of important mediators of angiogenesis, that is, IL-6, VEGF and IGF-1, in stromal cells. 6 MM cells also display an autonomous angiogenic activity; in fact, MM cells derived from the BM of patients with active MM display a higher proangiogenic activity in vitro when compared with inactive MM or MGUS. 69 In part this could be because of the ability of MM cells to autonomously express factors triggering or facilitating angiogenesis, among which VEGF, MMP-9 and IL-6 are reported to be under Notch control. 6, 61, 62 Deregulated Notch ligands on MM cells may influence new vessel formation by directly activating Notch signaling on BM-ECs as well. ECs are generated by mature ECs from pre-existing vessels or by endothelial progenitor cells (EPCs). 67 Notch signaling controls the specification between 'tip' and 'stalk' cells during new vessel formation in developmental angiogenesis and tumor neoangiogenesis. 70 Endothelial cells express the Notch receptors, Notch1/4, the DSL ligands, Dll1/4, and Jagged1/2. 71 Specifically, Dll4 is expressed by the tip cell 72 that sends signals to the surrounding cells but downregulates its own intracellular Notch signaling by lateral inhibition. On the contrary, stalk cells are prone to receive signals, and accordingly display higher Notch activation levels. 71, 72 In this scenario, how does MM cells affect the neoangiogenesis process? Through Jagged1 and Jagged2, MM cells may activate Notch1 and Notch4 in ECs. Notch pathway activation is expected to restrict new vessel formation. This is confirmed by the evidence in mouse retina that Jagged1-stimulated Notch signaling leads to reduced tip formation and filopodia extension; hosts (Dll4 heterozygous) display an increased sprouting angiogenesis. Nonetheless, such unbalanced angiogenesis is not productive, as abundant tumor vessels are poorly perfused and cause unexpected hypoxia, with reduction in tumor growth. 73 Consistently, Notch signaling triggered by Dll4-expressing tumor cells inhibits new vessel formation and branching, which is compensated by increased vessel diameter and perfusion. Such altered vascular structure is typical of chaotic and aberrant tumor neoangiogenesis, and is characterized by abnormal blood flow and increased permeability, thus promoting tumor growth. 74 BM-EPC participation in the formation of tumor vasculature increases during the transition from MGUS to MM, and Notch signaling regulates BM-EPC number and functions. 43 RBP-Jdeficient EPCs showed poor ability of adhering, migrating and forming vessel-like structures, as compared with RBP-J-expressing EPCs. 43 The molecular mechanisms underlying the Notchmediated control of EPCs function has yet to be completely elucidated. Nevertheless, the evidence that EPC recruitment to the BM is triggered through CXCR4 engagement by SDF1, 43 and our recent results indicating that Notch signaling may control SDF1 secretion by human MM cell lines, 44 suggest that the infiltration of MM cells in the BM may potentiate EPC recruitment by Notchdependent SDF1 secretion.
ADHESION TO THE ECM AND STROMAL CELLS: RESCUING MM FROM CHEMOTHERAPY-INDUCED DEATH
Malignant cell adhesion to the BM stroma is one important cause of the retention of MM cells to the BM, which determines the clinical features of the disease. 75 The BM stroma is a complex architecture of ECM molecules, namely fibronectin, hyaluronan, collagens and BMSCs. Malignant plasma cells efficiently adhere to all of these components, thus taking advantage of adhesion molecule activation signals, which counteract the growth arrest and apoptotic stimuli triggered by chemotherapeutic drugs. 13 Resistance to chemotherapy is one of the most relevant obstacles in the treatment of patients with MM. 76 Therefore, improving our understanding of the molecular mechanisms that participate in the adhesion process is particularly relevant in a clinical setting.
Notch receptors and their ligands play a central role in MM cell adhesive behavior as illustrated in Figure 2 .
9,16,17 Indeed, Nefedova et al. 16 found that Notch receptors, mainly Notch1 and Notch2, are aberrantly activated by MM cell homotypic interactions, but their signals can be further enhanced upon direct contact with BMSCs expressing Jagged1 and Dll1. Such activation was required for BMSCs to improve MM cell resistance against melphalan and mitoxantrone. The proposed mechanism involves BMSC ability to induce a p21-driven cell cycle slowdown via Notch. 16 In addition, Notch signaling can also be activated by MM cells into BMSCs as a number of studies evidenced the expression of Notch receptors by nontumoral BM-residing cells. 10, 17, 18 This results in the overexpression of protective factors by BMSCs. Indeed, as previously reported, MM cells are able to induce IL-6, VEGF and IGF-1 expression and secretion by BMSCs, which mediate a significant promotion of MM drug resistance. 6 Differently from BMSC adhesion, where different cells (tumoral and nontumoral) send and receive signals, adhesion to the ECM only triggers intracellular pathways within the malignant plasma cell itself. 77 MM cells display preferential adhesion to ECM components, including laminin, the microfibrillar collagen type VI and fibronectin, via the b1 integrin. 78 As reported above, the affinity of b1-containing integrin complexes is controlled by Notch through R-Ras 56 and possibly through CXCR4. 28, 44 In addition, Notch-mediated ability of MM cells to increase SDF1 level 44 in the BM may further influence MM adhesive properties by autonomous activation of the CXCR4 signaling.
UNBALANCE OF BONE METABOLISM: OSTEOLYTIC DISEASE AND ITS CONTRIBUTION TO TUMOR PROGRESSION
The interactions between the different cell types in MM microenvironment contribute to create a vicious cycle, resulting in a dysregulation of the equilibrium between bone formation and bone resorption with consequent bone osteolysis. MM is unique among hematological malignancies for its association with OCmediated skeletal destruction that leads to hypercalcemia, bone pain and increased risk of fractures, which represent the biggest problems in the life of patients. In addition, the increased osteoclastogenesis plays a crucial role in MM progression. Indeed, OCs play an active role, cooperating with MM cells to produce VEGF and osteopontin, increasing angiogenesis and stimulating vascular endothelial cells to secrete IL-6 and IL-8 and promoting OC formation. 79 In turn, mature OCs support long-term survival and proliferation of MM cells, 75 and through bone matrix degradation promote transforming growth factor-b (TGF-b) release, 80 whose role in antagonizing the patient's antitumor immune responses will be reviewed in the next section.
Bone formation by osteoblasts is inhibited by their physical interaction with MM cells 81 and by soluble factors such as Wnt antagonists DKK1. 82 On the other side, MM cells promote osteoclastogenesis, inducing BMSCs to increase the production of receptor activator of nuclear factor (NF)-kB ligand (RANKL) while hampering the expression of its decoy receptor osteoprotegerin, the net effect being the inhibition of OC precursors. 83 MM cells can also directly contribute to the pool of other pro-osteoclastogenic chemokines, such as MIP-3a 34 and MIP-1a, 33 in the BM microenvironment. The role of the CXCR4/ SDF1 pathway is more complex and the CXCR4 signaling requires a fine tuning during OC differentiation. In fact, although SDF1 is able to recruit circulating OC precursors and to stimulate their 84 disruption of CXCR4 signaling induces an accelerated OC differentiation, increasing tumor-associated osteoclastogenesis. 85 The Notch pathway plays a key role in skeletal development and remodeling. In the following paragraphs and in Figure 4 , we will try to illustrate the current knowledge on the Notch role in the MM-induced osteolysis by complementing the few evidences obtained in the MM setting with the knowledge on Notch function in skeletal development and remodeling.
The Notch signaling is able to block the maturation of the early OB pool by inhibiting the Wnt/b-catenin pathway in OB precursors. 86 Therefore, we may suppose that MM cell-mediated activation of the Notch pathway in mesenchymal precursors impairs OB maturation.
Notch activity is finely regulated during osteoclastogenesis and has distinct effects according to the different ligands and the receptor isoforms that are involved in the signaling. Notch1 and Notch3 have been reported to suppress osteoclastogenesis 87 whereas Notch2 is upregulated during RANKLinduced osteoclastogenesis and plays a critical role in the late stage of OC differentiation in association with NF-kB. 88 The role of the Notch ligands seems to vary depending on the Notch isoform they engage. Yamada et al. 89 showed that Dll1 inhibits OC development through Notch1, whereas a recent work from Sekine et al. 90 demonstrates that Dll1 enhances osteoclastogenesis by activating Notch2. These data suggest that MM cells may boost the OC differentiation process by the engagement of a particular Notch receptor (possibly Notch2) expressed by OC precursors. In addition, MM cells are likely to contribute to increase the BM concentration of SDF1 through a Notch-driven autonomous expression of SDF1, 44 therefore promoting the CXCR4-mediated recruitment and fusion of OC precursors. 84 Despite the complexity of Notch signaling modulation in osteoclastogenesis, and the paucity of information about its role in MM-mediated osteoclastogenesis, it seems clear that Notch signaling activated by MM cells is necessary for OC activity. Schwarzer et al. 91 demonstrate that GSI15 is able to impair OC activation and to induce apoptosis in MM cells co-cultured with OC, suggesting that the Notch pathway can be a rational target for the therapy of MM-associated bone disease.
These reports emphasize the complexity of Notch role in bone resorption triggered during MM progression, highlighting the need of further studies to elucidate the molecular mechanisms involved in this process.
ESCAPING THE IMMUNE SURVEILLANCE: A DEFECTIVE IMMUNE MICROSYSTEM
The relationship between MM cells and the BM microenvironment modulates the levels of different immunologically active compounds. Among these, TGF-b, IL-10 and IL-6 play central roles. The main functions of TGF-b in the immune system are maintaining tolerance and mitigating inflammatory responses of immune cells. MM cells were shown to abnormally produce TGF-b, which suppresses antitumor T-cell responses by inhibiting IL-2, 92 and by stimulating the proliferation of T regulatory cells. 93 It is known that Notch potentiates the suppressive effect of T regulatory cells by upregulating the TGF-b receptor II (TGF-bRII), 94 indicating that MM cells might increase T-cell sensitivity to TGF-b through the induction of Notch pathway in T helper (Th) cells within the BM niche. Interestingly, TGF-b is released from the bone matrix in an active form by osteoclastic resorption; 80 this, as above reported, requires an active Notch signaling in OCs mediated by their interaction with MM cells 91 and further benefits of the Notchmediated production of SDF1 by MM cells. 44 Noteworthy, Notch plays a key role in the conversion of proinflammatory Th1 cells into suppressive T regulatory cell by inducing IL-10 production. 95 Differently from other malignancies, where IL-17-secreting T cells (Th17) have been shown to drive tumor-antigen-specific antitumor immunity, a recent study clearly demonstrated that IL-17 promoted MM cell growth and inhibited tumor-specific immune functions in patients. 96 As Notch1 was found to be activated in human in vitro polarized Th17 cells and the blockade of Notch signaling significantly downregulated Th17-associated cytokines, 97 it may be hypothesized that Jagged1/2-expressing MM cells are able to support the expression of IL-17 in a local microenvironment that is otherwise suppressive, being characterized by elevated TGF-b, IL-10, IL6 and T regulatory cells.
Dendritic cell (DC) dysfunction is characteristic of MM patients. Understanding the mechanisms underlying this DC deficiency is critical, as DCs represent the bridge between innate and adaptive responses and are the most relevant inducers of antitumor T-cell responses. DCs have been demonstrated to be recruited in the tumor environment, 98 but the immunological properties of DCs are impaired upon interaction with MM cells. DC dysfunctions in MM patients include poor expression of the costimulatory molecules CD80/86 and inefficient antigen presentation and processing, consistent with an immature DC phenotype. 99 Two soluble factors, that is, IL-6 and VEGF, are well known for their ability to prevent DC differentiation and function, 100 and are overexpressed by fibroblasts in the MM BM microenvironment under Notch control. (1) Notch activation by homotypic or heterotypic interactions is necessary for SDF1 secretion, resulting in pre-OC recruitment to the BM; (2) MM cells secrete osteogenic chemokines and (3) through Jagged1 and Jagged2 contribute to Notch2 activation in pre-OCs, a critical step in the late stage of OC differentiation; (4) pre-OC differentiation is also promoted by interaction between MM cells and BMSCs, resulting in the production of the differentiation factor, RANKL; (5) ECs can also stimulate osteoclastogenesis by secreting IL-6 and IL-8; (6) Notch signaling is necessary for OC activation: this results in bone resorption with consequent release of TGF-b from the bone matrix that promotes the impairment of antitumor immune response. Mature OCs release soluble factor that stimulates MM cell survival and proliferation and VEGF that promotes angiogenesis. Up to now, the only strategy to block Notch signaling that has been attempted in human subjects relies on the inhibition of the g-secretase complex. The available scientific literature on g-secretase inhibition points out that treatment-related toxicities prevent the use of GSIs long enough to achieve a therapeutic effect. The majority of drugs to modulate Notch signaling were originated to treat a neoplasia-unrelated condition, namely Alzheimer's disease, as amyloid precursor protein is cleaved by the g-secretase complex similarly to Notch receptors. DFK167 was the first g-secretase-specific inhibitor to be designed. 101 Later on, an increasing number of GSIs was characterized, mainly transition-state analogs based on hydroxyethylamine, helical peptides and dipeptide structures, such as Compound E, DAPT, LY-411,575 and LY-450,139, 102-104 all of which display high specificity for the g-secretase. Despite initial promising results in preclinical models, the enthusiasm for GSIs was soon tempered by animal and human safety trials: because of interference with Notch signaling, Alzheimer patients treated with GSIs showed gastrointestinal bleeding and immunosuppression. 105 Therefore, increasing efforts are being put in the development of Notch-sparing GSIs that are designed to be more amyloid precursor protein selective (up to 3000-fold). 106 However, it is this 'off-target' effect that prompted the use of GSIs in treating Notch-related cancers. Despite different dosages, studies involving GSIs for the treatment of cancer evidenced similar obstacles as reported for GSIs in the treatment of Alzheimer's disease. Indeed, although Notch represents a promising target in cancer therapy, GSI-induced Notch inhibition has been proven to cause significant gastrointestinal toxicity because of the increased formation of secretory goblet cells in the intestine, a process known as intestine metaplasia, ultimately resulting in dose-limiting toxicity. 107, 108 A possible strategy to partially overcome this obstacle relies in the use of GSIs in combinatorial drug regimens. The recent work by Samon et al. 109 in T-cell acute lymphoblastic leukemia showed that the co-administration of the clinically relevant GSI, PF-03084014, and dexamethasone not only produced a synergistic antileukemia effect, but importantly reversed the PF-03084014-induced intestine metaplasia, thus mitigating GSI toxicity. Although very promising in preclinical murine models, careful evaluation in human subjects is still needed.
An alternative may be represented by the selective inhibition of Notch isoforms. Interestingly, intestine metaplasia is because of the simultaneous inhibition of Notch1 and Notch2, suggesting that it is therapeutically promising to independently target Notch1 or Notch2. 110 Such strategy has been referred to as 'Notch immunotherapy'. Notch1, 2, and 3-antagonizing antibodies were developed, which bind to and stabilize the extracellular negative regulatory domain of Notch, antagonizing the conformational change required for the cleavage by ADAM protease following ligand binding. 111 It was reported that such antibodies are effective at relatively low concentrations even in negative regulatory domain-mutated cancer cell lines. 111 Additionally, Notch1-and Notch3-tailored antibodies were shown not only to block ADAM processing, but also to compete for ligand binding, although this additional effect is seen at higher concentrations. 111 At present, a number of Notch paralogs neutralizing antibodies are being evaluated in preclinical trials, whereas the anti-Notch1 antibody, OMP-59R5, is in phase I clinical study for solid tumors (ClinicalTrials.gov no. NCT01277146).
Furthermore, Notch signaling components have also been targeted. Dll4-blocking antibodies are currently under clinical evaluation for pancreatic cancer (NCT01189929) and solid tumors (NCT00744562). A different targetable member of the Notch signaling pathway is the transcriptional complex resulting from intracellular Notch, the DNA-bound transcription factor CSL, and the co-activator proteins of the mastermind-like family (MAML). A hydrocarbon-stapled peptide, SAHM1, has been reported to be a dominant-negative form of MAML-1, thus preventing the stabilization of the Notch-CSL-MAML transcriptional complex. 112 So far, SAHM1 was shown to efficiently block Notch signaling in cultured leukemic cells and in a murine model of acute T-cell leukemia without causing any evident toxicity or gastrointestinal side effect. 112 However, extreme care should be used when planning Notchtailored therapies because of the risk of facilitating neoplasias in which Notch exerts a tumor-suppressor role, such as non-melanoma skin carcinomas, head and neck squamous cell carcinoma and chronic myelomonocytic leukemia. Noteworthy, a recent phase III advanced long-term clinical trial based on the most advanced and specific GSI, Semagacestat, for the treatment of Alzheimer's disease, indicated an increased risk of skin cancer. 113 On the other hand, the inhibition of specific Notch ligands could significantly mitigate the adverse effects on goblet cells with high efficacy against tumors showing Notch ligand upregulation, such as MM, with possibly low risk of significant Notch inhibition in tissues where it functions as a tumor suppressor because of redundancy in ligand expression. Indeed, although the most relevant Notch pathway deregulation in MM is the overexpression of Jagged2 as discussed above, potential Notch inhibition-induced cancers develop in tissues where Notch activation likely relies on different mechanisms. For instance, the most abundant Notch ligand in the skin are Jagged1 and Dll1, 114 whereas the growth suppression effect of Notch1 in chronic myelomonocytic leukemia requires Dll4 engagement; 115 consequently, the selective targeting of Jagged2 may not increase the risk of skin carcinomas or chronic myelomonocytic leukemia.
Therefore, we hold that antibodies blocking specific Notch ligands may represent a potentially effective alternative to GSI in MM, as Jagged but not Dll ligand overexpression by MM cells is the major cause of Notch signaling abnormalities in this pathology, 6, 15, 18 whereas no mechanism of ligand-independent activation of Notch signaling, such as Notch receptor gain-offunction mutations, has been reported to date in MM. To this concern, Jagged1-blocking antibodies have been developed for the treatment of aberrant immune activation such as encephalomyelitis, but in in vitro studies only. 116 On the other hand, no Jagged2-neutralizing antibody has been produced so far, indicating the need of implementing and testing Jagged-tailored immunotherapies for MM.
